home.aspx

 
.

LITIGATION, REGULATORY AND TRANSACTIONAL TRENDS IN THE PHARMA AND HEALTHCARE SECTOR

March 25, 2020 | (12:00PM)
USA (United States of America)
SHARESHARESHARE
The past years have seen significant disruptions in the pharmaceutical and healthcare industry, brought about by litigation and regulatory developments as well as transactional trends that continue to emerge in the backdrop. As discussions on healthcare system improvement intensify, changes in the landscape are likely to speed up this year. While the Affordable Care Act’s (ACA’s) constitutionality will keep the spotlight, other important cases that pharma and healthcare providers should also follow include price transparency and new product liability risks resulting from the use of artificial intelligence (AI) in drug and medical device development, as well litigations brought State Attorneys Generals and municipalities asserting novel theories of tort liability. A number of existing bills, such as those aimed at lowering drug prices, improving cybersecurity, and battling opioid misuse, are also expected to come back into focus as the presidential election draws near. In terms of transactional trends, the high level of healthcare mergers & acquisitions (M&A) activity in 2019 is predicted to continue this 2020.